Cytokine mediation of experimental heart failure-induced anhedonia

American Journal of Physiology - Regulatory Integrative and Comparative Physiology

Volumn 284, Issue 3 53-3, 2003, Pages

  Grippo, Angela J ^a,c   Francis, Joseph ^b,c   Weiss, Robert M ^b,d   Felder, Robert B ^b,d   Johnson, Alan Kim ^a,b,c  

^a E11 SSH   (United States)

^b UNIVERSITY OF IOWA   (United States)

^c UNIVERSITY OF IOWA   (United States)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Cardiovascular disease; Depression; Etanercept; Immune system; Tumor necrosis factor

Indexed keywords

CYTOKINE; DRUG VEHICLE; ETANERCEPT; TUMOR NECROSIS FACTOR ALPHA;

ANHEDONIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN DEPTH STIMULATION; CARDIOVASCULAR DISEASE; COMORBIDITY; CORONARY ARTERY DISEASE; DEPRESSION; DRUG EFFECT; HEART FAILURE; IMMUNE DEFICIENCY; IMMUNE SYSTEM; MALE; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RAT;

EID: 0037340140     PISSN: 03636119     EISSN: None     Source Type: Journal    
DOI: 10.1152/ajpregu.00430.2002     Document Type: Article

References (40)

1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (4th ed.). Washington, DC: American Psychiatric Association, 1994.
2. Anisman H, Kokkinidis L, Borowski T, and Merali Z. Differential effects of interleukin (IL)-1β IL-2, and IL-6 on responding for rewarding lateral hypothalamic stimulation. Brain Res 779: 177-187, 1998.
3. Aromaa A, Raitasalo R, Reunanen A, Impivaara O, Heliövaara M, Knekt P, Lehtinen V, Joukamaa M, and Maatela J. Depression and cardiovascular diseases. Acta Psychiatr Scand Suppl 377: 77-82, 1994.
4. Banks WA, Kastin AJ, and Broadwell RD. Passage of cytokines across the blood-brain barrier. Neuroimmunomodulation 2: 241-248, 1995.
5. Barefoot JC and Schroll M. Symptoms of depression, acute myocardial infarction, and total mortality in a community sample. Circulation 93: 1976-1980, 1996.
6. Carney RM, Rich MW, Freedland KE, Saini J, teVelde A, Simeone C, and Clark K. Major depressive disorder predicts cardiac events in patients with coronary artery disease. Psychosom Med 50: 627-633, 1988.
7. Connor TJ, Song C, Leonard BE, Merali Z, and Anisman H. An assessment of the effects of central interleukin-1β, -2, -6, and tumor necrosis factor-α administration on some behavioural, neurochemical, endocrine, and immune parameters in the rat. Neuroscience 84: 923-933, 1998.
8. Cytawa J and Tronjniar W. The pleasure system of the brain and its neurotransmitters. Pol J Pharmacol 31: 283-292, 1979.
9. Dantzer R. How do cytokines say hello to the brain? Neural vs. humoral mediation. Eur Cytokine Netw 5: 271-273, 1994.
10. Dunn AJ. Interactions between the nervous system and the immune system: implications for psychopharmacology. In: Psychopharmacology: the Fourth Generation of Progress, edited by Bloom FE and Kupfer DJ. New York: Raven, 1995, p. 719-731.
11. Dunn AJ, Wang J, and Ando T. Effects of cytokines on cerebral neurotransmission: comparison with the effects of stress. In: Cytokines, Stress, and Depression, edited by Dantzer R, Wollmann EE, and Yirmiya R. New York: Kluwer Academic/Plenum, 1999, p. 117-127.
12. Edmonds DE and Gallistel CR. Parametric analysis of brain stimulation reward in the rat. III. Effect of performance variables on the reward summation function. J Comp Physiol Psychol 87: 876-883, 1974.
13. Elenkov IJ, Chrousos GP, and Wilder RL. Neuroendocrine regulation of IL-12 and TNF-α/IL-10 balance. Clinical implications. Ann NY Acad Sci 917: 94-105, 2000.
14. Evangelou AM. Platelet-activating factor (PAF): implications for coronary heart and vascular diseases. Prostaglandins Leukot Essent Fatty Acids 50: 1-28, 1994.
15. Francis J, Weiss JM, Wei SG, Johnson AK, and Felder RB. Progression of heart failure after myocardial infarction in the rat. Am J Physiol Regul Integr Comp Physiol 281: R1734-R1745, 2001.
16. Francis J, Weiss RM, and Felder RB. Early increase in tumor necrosis factor-alpha after coronary artery ligation in rats (Abstract). Soc Neurosci Abstr (http://sfn.ScholarOne.com/itin2001/main.html), 2001.
17. Francis J, Weiss RM, Wei SG, Johnson AK, Beltz TG, Zimmerman K, and Felder RB. Central mineralocorticoid receptor blockade improves volume regulation and reduces sympathetic drive in heart failure. Am J Physiol Heart Circ Physiol 281: H2241-H2251, 2001.
18. Frasure-Smith N, Lespérance F, and Talajic M. Depression following myocardial infarction: impact on 6-month survival. JAMA 270: 1819-1825, 1993.
19. Glickman SE and Schiff BB. A biological theory of reinforcement. Psychol Rev 74: 81-109, 1967.
20. 2 receptor agonists on intracranial self stimulation in the rat. Psychopharmacology 140: 405-410, 1998.
21. Hopkins SJ and Rothwell NJ. Cytokines and the nervous system I: expression and recognition. Trends Neurosci 18: 83-88, 1995.
22. Ito BR, Schmid-Schönbein G, and Engler RL. Effects of leukocyte activation on myocardial vascular resistance. Blood Cells Mol Dis 16: 145-166, 1990.
23. Kapadia S, Dibbs Z, Kurrelmeyer K, Karla D, Seta Y, Wang F, Bozkurt B, Oral H, Sivasubramanian N, and Mann DL. The role of cytokines in the failing human heart. Cardiol Clin 16: 645-656, 1998.
24. Levine B, Kalman J, Mayer L, Fillit HM, and Packer M. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N Engl J Med 323: 236-241, 1990.
25. Miliaressis E, Rompre P-P, Laviolette P, Phillipe L, and Coulombe D. The curve-shift paradigm in self-stimulation. Physiol Behav 37: 85-91, 1986.
26. Montgomery AM, Rose IC, and Herberg LJ. 5-HT1A agonists and dopamine: the effects of 8-OH-DPAT and buspirone on brain-stimulation reward. J Neural Transm 83: 139-148, 1991.
27. Moreau J-L, Jenck F, Martin JR, Mortas P, and Haefely WE. Antidepressant treatment prevents chronic unpredictable mild stress-induced anhedonia as assessed by ventral tegmentum self-stimulation behavior in rats. Eur Neuropsychopharmacol 2: 43-49, 1992.
28. Olds J. Hypothalamic substrates of reward. Physiol Rev 42: 554-604, 1962.
29. Olds ME and Fobes JL. The central basis of motivation: intracranial self-stimulation studies. Annu Rev Psychol 32: 523-574, 1981.
30. Opp MR, Kapas L, and Toth LA. Cytokine involvement in the regulation of sleep. Proc Soc Exp Biol Med 201: 16-27, 1992.
31. Paxinos G and Watson C. The Rat Brain in Stereotaxic Coordinates (4th ed.). San Diego, CA: Academic, 1998.
32. Penninx BWJH, Beekman ATF, Honig A, Deeg DJH, Schoevers RA, van Eijk JTM, and van Tilburg W. Depression and cardiac mortality: results from a community-based longitudinal study. Arch Gen Psychiatry 58: 221-227, 2001.
33. Rothwell NJ and Hopkins SJ. Cytokines and the nervous system II: actions and mechanisms of action. Trends Neurosci 18: 130-136, 1995.
34. Schleifer SJ, Macari-Hinson MM, Coyle DA, Slater WR, Kahn M, Gorlin R, and Zucker HD. The nature and course of depression following myocardial infarction. Arch Intern Med 149: 1785-1789, 1989.
35. Sheridan FM, Dauber IM, McMurtry IF, Lesnefsky EJ, and Horwitz LD. Role of leukocytes in coronary vascular endothelial injury due to ischemia and reperfusion. Circ Res 69: 1566-1574, 1991.
36. Smith RS. The macrophage theory of depression. Med Hypotheses 35: 298-306, 1991.
37. Spiegel D. Cancer and depression. Br J Psychiatry Suppl 30: 109-116, 1996.
38. Spriggs DR, Sherman ML, Michie H, Arthor KA, Imamura K, Wilmore D, Frie E, and Kufe DW. Recombinant human tumor necrosis factor administered as a 24-hour intravenous infusion. A phase 1 and pharmacology study. J Natl Cancer Inst 80: 1039-1044, 1988.
39. Wong GHW and Goeddel DV. Tumor necrosis factor. In: Human Monocyte, edited by Zembala M and Asherson GL. San Diego, CA: Academic, 1989, p. 195-215.
40. Wyeth Pharmaceuticals. Enbrel/etanercept product information. Wyeth Pharmaceuticals. (http://www.enbrel.com/hcp/product_information/product_information.jsp), Sept. 18, 2002.